Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Roche Holding AGXSWX:RO -1.41%76 Equity-to-Asset is 0.34 as of Dec. 2025, which is 3% above its 10-year median of 0.33. GuruFocus rates XSWX:RO with a GF Score™ of 76/100 and a GF Value™ of CHF268.98 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Roche Holding AG ranks worse than 80.75% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Roche Holding AG's Total Stockholders Equity for the quarter that ended in Dec. 2025 was CHF33,802 Mil. Roche Holding AG's Total Assets for the quarter that ended in Dec. 2025 was CHF100,703 Mil.
Therefore, Roche Holding AG's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.34.
The historical rank and industry rank for Roche Holding AG's Equity-to-Asset or its related term are showing as below:
XSWX:RO'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.27 Med: 0.33 Max: 0.42
Current: 0.34
During the past 13 years, the highest Equity to Asset Ratio of Roche Holding AG was 0.42. The lowest was 0.27. And the median was 0.33.
XSWX:RO's Equity-to-Asset is ranked worse than 80.75% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs XSWX:RO: 0.34
Roche Holding AG (XSWX:RO) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Roche Holding AG Equity-to-Asset Related Terms
Roche Holding AG Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Roche Holding AG's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:RO vs LLY, JNJ, ABBV: Equity-to-Asset Comparison
For the Drug Manufacturers - General subindustry, Roche Holding AG's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Roche Holding AG Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Roche Holding AG's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Roche Holding AG's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Roche Holding AG (XSWX:RO) has a Equity-to-Asset of 0.34 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Roche Holding AG and its competitors. This is near median its historical median of 0.33. Over the past decade, Roche Holding AG's Equity-to-Asset has ranged from 0.27 to 0.42. According to the industry distribution chart, Roche Holding AG ranks #814 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 80.8%.
Is Roche Holding AG's Equity-to-Asset too high?
Roche Holding AG's current Equity-to-Asset of 0.34 is near median its 10-year median of 0.33. Over the past 10 years, this metric has ranged from a low of 0.27 to a high of 0.42. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Roche Holding AG's value of 0.34 is 44.3% below this industry median. Based on the distribution chart, Roche Holding AG ranks #814 out of 1008 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Roche Holding AG has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's Equity-to-Asset compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Roche Holding AG ranks #814 out of 1008 companies for Equity-to-Asset. This places Roche Holding AG in the lower half of its industry. The industry median Equity-to-Asset is 0.61. Roche Holding AG's value of 0.34 is 44.3% below this benchmark. Historically, Roche Holding AG's own Equity-to-Asset has ranged from 0.27 to 0.42 over the past decade. While the company's 10-year median is 0.33 vs. the industry median of 0.61, Roche Holding AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Roche Holding AG's current Equity-to-Asset of 0.34 is 44.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Roche Holding AG and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Roche Holding AG's current Equity-to-Asset is 0.34, which is near median its own 10-year median of 0.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (XSWX:RO) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF268.98, compared to a current price of CHF336.20 — trading 25% above its estimated fair value. The current Equity-to-Asset is 0.34, which is near median its 10-year median of 0.33 and 44.3% below the Drug Manufacturers industry median of 0.61. Roche Holding AG's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Roche Holding AG (XSWX:RO), the current Equity-to-Asset is 0.34 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Roche Holding AG (XSWX:RO) Overvalued in 2026?
Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued.
The current stock price of CHF336.20 is trading 25% above its estimated GF Value™ of CHF268.98.
GuruFocus considers Roche Holding AG to be Modestly Overvalued.
Key valuation signals for XSWX:RO:
Equity-to-Asset: 0.34 (near median its 10-year median of 0.33)
GF Value™: CHF268.98 vs. price of CHF336.20 (25% above fair value)
Industry Position: 44.3% below the Drug Manufacturers median (#814 of 1008)
No single metric tells the full story. See the XSWX:RO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
76GF Score
Get the complete analysis for XSWX:RO
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:RO has been successfully added to your 
